查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1859760

全球基因组学市场预测（至2032年）：依产品、功能、交付模式、技术、应用、最终用户和地区进行分析

Genomics Market Forecasts to 2032 - Global Analysis By Product (Instruments, Consumables and Software & Services), Function, Delivery Model, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2025 年，全球基因组学市场规模将达到 443 亿美元，到 2032 年将达到 1,291 亿美元，预测期内复合年增长率为 16.5%。

基因组学是分子生物学的一个分支，专注于基因组（生物体内完整的DNA序列）的结构、功能、演化、定位和编辑。它分析基因及其相互作用，以了解生物过程、疾病机制和遗传变异。基因组学在个人化医疗、农业、生物技术和环境科学中发挥着至关重要的作用。定序、生物资讯学和基因编辑等技术使研究人员能够识别遗传标记、开发标靶治疗并改良作物性状。透过破解生命的遗传蓝图，基因组学推动了医疗保健和整个科学领域的创新，并为遗传学、健康风险和演化生物学提供了新的见解。

对个人化医疗的需求日益增长

个人化医疗的日益普及是基因组学市场发展的关键驱动力。透过根据个别基因谱量身订做治疗方案，医疗服务提供者可以改善治疗效果并减少副作用。基因组学能够实现精准诊断、标靶治疗和预测风险评估，尤其是在肿瘤学、心臟病学和罕见疾病领域。随着病患和医疗服务提供者对个人化医疗服务的需求不断增长，基因组检测和数据分析的需求也日益增加，这得益于定序技术的进步以及与电子健康记录的整合。

基因组设备和服务高成本

儘管基因组学市场具有巨大的变革潜力，但仍面临显着的成本限制。定序平台、试剂和生物资讯工具的高昂成本限制了其普及，尤其是在资源匮乏的地区。此外，对熟练人员和基础设施的需求也增加了营运成本。这些经济障碍阻碍了基因组学在临床和农业领域的广泛应用。虽然价格正在逐步下降，但对于小规模实验室和新兴市场而言，负担能力仍然是一个挑战，因此需要可扩展的解决方案和官民合作关係来在全球扩展基因组学能力。

定序技术的进步

测序方法的创新带来了巨大的市场机会。次世代定序(NGS) 和新兴平台能够提供更快、更准确、更有经济效率的基因组分析。这些进步使得基因组分析在诊断、药物研发和群体基因组学等领域拥有广泛的应用前景。随着定序分析的普及，研究人员和临床医生将能够更精确地研究复杂的基因交互作用和罕见突变。自动化和数据解读技术的持续进步将进一步强化基因组学在个人化医疗和全球健康计画中的作用。

资料隐私和伦理问题

资料隐私和伦理挑战对市场构成重大威胁。处理敏感的基因资讯引发了人们对知情同意、资料安全和滥用的担忧。患者可能不愿意在没有明确保障措施的情况下共用其基因组数据，尤其是在直接面向消费者的检测中。法律规范因地区而异，这使得合规性和跨境研究更加复杂。围绕基因编辑、歧视和基因数据所有权的伦理困境将进一步加剧公众的关注。解决这些问题需要透明的政策、强大的网路安全和伦理监督，以维护公众信任。

新冠疫情的影响：

新冠疫情加速了基因组学研究和应用，尤其是在病毒序列测定和疫苗研发方面。基因组监测在追踪病毒变异和指导公共卫生应对措施方面发挥了关键作用。此次危机也凸显了快速诊断和个人化治疗策略的重要性。儘管初期中断影响了供应链和研究进度，但对基因组学基础设施的长期投资却大幅成长。疫情凸显了基因组数据在感染疾病管理中的价值，并加强了其在常规医疗保健和全球紧急准备工作中的应用。

预计在预测期内，微阵列细分市场将成为最大的细分市场。

由于微阵列技术在基因表现分析、基因型鉴定和生物标记发现等领域的广泛应用，预计在预测期内，微阵列技术将占据最大的市场份额。微阵列技术提供高通量分析，并为大规模研究提供了一种经济高效的解决方案。其能够同时检测数千个基因，使其在研究、诊断和药物基因组学领域中具有重要价值。随着对个人化医疗和疾病风险评估需求的不断增长，微阵列技术仍然是学术机构、临床实验室和生物技术公司寻求可靠基因组学见解的首选工具。

预计法医学基因组学领域在预测期内将实现最高的复合年增长率

预计在预测期内，法医学基因组学领域将呈现最高的成长率，因为DNA定序和生物资讯学的进步正在彻底改变刑事调查、亲子鑑定和灾难受害者身分识别。基因组分析工具能够对劣化或有限的样本进行精确分析，从而提高法医学案件的准确性和解析度。对快速、便携式检测解决方案以及与国家资料库整合的需求不断增长，进一步推动了该技术的应用。随着法律体系越来越接受基因组证据，法医学基因组学有望在执法机关和司法领域中迅速发展。

最大份额地区：

预计亚太地区将在预测期内占据最大的市场份额。这主要得益于该地区人口的快速增长、医疗保健投资的增加以及人们对基因检测日益增长的认知，这些因素共同推动了该地区的需求。中国、印度和日本等国家正透过政府倡议和私部门合作来促进基因组研究。不断扩大的生物技术基础、有利的法规环境以及人们对个人化医疗日益增长的兴趣，都有助于巩固亚太地区的市场主导地位。凭藉强大的学术机构和新兴新兴企业，亚太地区在基因组创新和普及方面处于领先地位。

复合年增长率最高的地区：

由于北美地区拥有强大的研究基础设施、高额的医疗保健支出以及对先进技术的早期应用，预计该地区在预测期内将呈现最高的复合年增长率。该地区在精准医疗和生物资讯学领域的领先地位正在推动市场的快速成长。政府的资金支持、卓越的学术水平和强大的产业实力正在推动诊断、治疗和农业领域的创新。监管支持和公众意识的提高也进一步促进了技术的普及应用。随着基因组学日益成为医疗保健和生命科学不可或缺的一部分，北美将继续引领全球扩张的脚步。

免费客製化服务：

订阅本报告的用户可享有以下免费客製化服务之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 原始研究资料
    • 次级研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球基因体学市场（依产品划分）

  • 装置
    • 音序器和放大器
    • 样品製备设备
    • DNA/RNA分析仪
  • 消耗品
    • 试剂和试剂盒
    • 面板和晶片
  • 软体和服务
    • 生物资讯软体
    • 数据分析服务
    • 云端基础的解决方案
    • 维护和支援服务

6. 全球基因体学市场按功能划分

  • 基因组序列分析
  • 表观基因分析
  • 基因表现分析
  • 基因型鉴定

7. 全球基因体学市场依交付模式划分

  • 本地部署
  • 基于网路的
  • 云端基础的

8. 全球基因体学市场（依技术划分）

  • 定序
    • 次世代定序（NGS）
    • 桑格定序
    • 第三代定序
  • PCR
    • 定量PCR
    • dPCR
  • 微阵列
  • CRISPR
  • 表观基因

9. 全球基因体学市场（按应用划分）

  • 诊断
    • 癌症诊断
    • 罕见疾病诊断
    • 感染疾病诊断
  • 药物发现与开发
  • 法医学基因组学
  • 精准医疗
  • 农业和动物研究
  • 其他用途

第十章：全球基因体学市场（以最终用户划分）

  • 医院和诊所
  • 诊断检查室
  • 研究和学术机构
  • 製药和生物技术公司
  • 合约研究组织（CRO）

第十一章：全球基因组学市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与併购
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十三章：企业概况

  • Illumina
  • Eurofins Scientific
  • Thermo Fisher Scientific
  • GenScript Biotech
  • BGI Genomics
  • Intellia Therapeutics
  • Agilent Technologies
  • CRISPR Therapeutics
  • Roche
  • Oxford Nanopore Technologies
  • Bio-Rad Laboratories
  • Pacific Biosciences
  • QIAGEN
  • 10x Genomics
  • Natera
Product Code: SMRC31984

According to Stratistics MRC, the Global Genomics Market is accounted for $44.3 billion in 2025 and is expected to reach $129.1 billion by 2032 growing at a CAGR of 16.5% during the forecast period. Genomics is the branch of molecular biology focused on the structure, function, evolution, mapping, and editing of genomes-the complete set of DNA within an organism. It involves analyzing genes and their interactions to understand biological processes, disease mechanisms, and genetic variation. Genomics plays a vital role in personalized medicine, agriculture, biotechnology, and environmental science. Techniques such as sequencing, bioinformatics, and gene editing enable researchers to identify genetic markers, develop targeted therapies, and improve crop traits. By decoding the genetic blueprint of life, genomics drives innovation across healthcare and science, offering insights into heredity, health risks, and evolutionary biology.

Market Dynamics:

Driver:

Rising Demand for Personalized Medicine

The growing emphasis on personalized medicine is a major driver of the genomics market. By tailoring treatments to individual genetic profiles, healthcare providers can improve outcomes and reduce adverse reactions. Genomics enables precise diagnosis, targeted therapies, and predictive risk assessments, especially in oncology, cardiology, and rare diseases. As patients and providers seek more customized care, demand for genomic testing and data analytics continues to rise, supported by advances in sequencing technologies and integration with electronic health records.

Restraint:

High Cost of Genomic Equipment and Services

Despite its transformative potential, the genomics market faces significant cost-related restraints. High expenses for sequencing platforms, reagents, and bioinformatics tools limit accessibility, particularly in low-resource settings. Additionally, the need for skilled personnel and infrastructure adds to operational costs. These financial barriers hinder widespread adoption in clinical and agricultural applications. While prices are gradually declining, affordability remains a challenge for small labs and emerging markets, necessitating scalable solutions and public-private partnerships to expand genomic capabilities globally.

Opportunity:

Advancements in Sequencing Technologies

Technological innovation in sequencing methods presents a major opportunity for the market. Next-generation sequencing (NGS) and emerging platforms offer faster, more accurate, and cost-effective genome analysis. These advancements enable broader applications in diagnostics, drug development, and population genomics. As sequencing becomes more accessible, researchers and clinicians can explore complex genetic interactions and rare variants with greater precision. Continued progress in automation and data interpretation will further enhance genomics' role in personalized medicine and global health initiatives.

Threat:

Data Privacy and Ethical Concerns

Data privacy and ethical challenges pose a significant threat to the market. Handling sensitive genetic information raises concerns about consent, data security, and misuse. Patients may be reluctant to share genomic data without clear safeguards, especially in direct-to-consumer testing. Regulatory frameworks vary across regions, complicating compliance and cross-border research. Ethical dilemmas around gene editing, discrimination, and ownership of genetic data further intensify scrutiny. Addressing these issues requires transparent policies, robust cybersecurity, and ethical oversight to maintain public trust.

Covid-19 Impact:

The COVID-19 pandemic accelerated genomics research and applications, particularly in viral sequencing and vaccine development. Genomic surveillance played a critical role in tracking mutations and guiding public health responses. The crisis also highlighted the importance of rapid diagnostics and personalized treatment strategies. While initial disruptions affected supply chains and research timelines, long-term investment in genomics infrastructure surged. The pandemic underscored the value of genomic data in managing infectious diseases and reinforced its integration into routine healthcare and global preparedness efforts.

The microarrays segment is expected to be the largest during the forecast period

The microarrays segment is expected to account for the largest market share during the forecast period, due to its widespread use in gene expression profiling, genotyping, and biomarker discovery. Microarrays offer high-throughput analysis and cost-effective solutions for large-scale studies. Their ability to simultaneously examine thousands of genes makes them valuable in research, diagnostics, and pharmacogenomics. As demand grows for personalized medicine and disease risk assessment, microarrays remain a preferred tool for academic institutions, clinical laboratories, and biotech companies seeking reliable genomic insights.

The forensic genomics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the forensic genomics segment is predicted to witness the highest growth rate, due to advances in DNA sequencing and bioinformatics are revolutionizing criminal investigations, paternity testing, and disaster victim identification. Genomic tools enable precise analysis of degraded or limited samples, improving accuracy and resolution in forensic cases. Growing demand for rapid, portable testing solutions and integration with national databases further drives adoption. As legal systems embrace genomic evidence, forensic genomics is poised for rapid expansion across law enforcement and judicial applications.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to rapid population growth, increasing healthcare investments, and rising awareness of genetic testing fuel regional demand. Countries like China, India, and Japan are advancing genomics research through government initiatives and private sector collaboration. Expanding biotech hubs, favorable regulatory environments, and growing interest in personalized medicine contribute to market dominance. With a strong base of academic institutions and emerging startups, Asia Pacific leads in genomic innovation and accessibility.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust research infrastructure, high healthcare spending, and early adoption of advanced technologies. The region's leadership in precision medicine and bioinformatics supports rapid market growth. Government funding, academic excellence and strong industry presence foster innovation across diagnostics, therapeutics, and agriculture. Regulatory support and public awareness further enhance adoption. As genomics becomes integral to healthcare and life sciences, North America continues to set the pace for global expansion.

Key players in the market

Some of the key players in Genomics Market include Illumina, Eurofins Scientific, Thermo Fisher Scientific, GenScript Biotech, BGI Genomics, Intellia Therapeutics, Agilent Technologies, CRISPR Therapeutics, Roche, Oxford Nanopore Technologies, Bio-Rad Laboratories, Pacific Biosciences, QIAGEN, 10x Genomics, and Natera.

Key Developments:

In July 2025, Thermo Fisher Scientific has expanded its strategic partnership with Sanofi by acquiring Sanofi's state-of-the-art sterile fill-finish and packaging facility in Ridgefield, New Jersey. This acquisition enhances Thermo Fisher's U.S. manufacturing capabilities, enabling the production of critical medicines for Sanofi and meeting the growing demand from pharmaceutical and biotech customers.

In May 2025, RoosterBio and Thermo Fisher Scientific have announced collaboration aimed at advancing the development and manufacturing of cell and exosome therapies for degenerative diseases. This partnership combines RoosterBio's expertise in human mesenchymal stem/stromal cells (hMSCs) and exosome technologies with Thermo Fisher's global contract manufacturing capabilities.

Products Covered:

  • Instruments
  • Consumables
  • Software & Services

Functions Covered:

  • Genome Sequencing
  • Epigenomic Analysis
  • Gene Expression Profiling
  • Genotyping

Delivery Models Covered:

  • On-Premise
  • Web-Based
  • Cloud-Based

Technologies Covered:

  • Sequencing
  • PCR
  • Microarrays
  • CRISPR
  • Epigenomics

Applications Covered:

  • Diagnostics
  • Drug Discovery & Development
  • Forensic Genomics
  • Precision Medicine
  • Agriculture & Animal Research
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutions
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Genomics Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
    • 5.2.1 Sequencers & Amplifiers
    • 5.2.2 Sample Preparation Instruments
    • 5.2.3 DNA/RNA Analyzers
  • 5.3 Consumables
    • 5.3.1 Reagents & Kits
    • 5.3.2 Panels & Chips
  • 5.4 Software & Services
    • 5.4.1 Bioinformatics Software
    • 5.4.2 Data Analysis Services
    • 5.4.3 Cloud-based Solutions
    • 5.4.4 Maintenance & Support Services

6 Global Genomics Market, By Function

  • 6.1 Introduction
  • 6.2 Genome Sequencing
  • 6.3 Epigenomic Analysis
  • 6.4 Gene Expression Profiling
  • 6.5 Genotyping

7 Global Genomics Market, By Delivery Model

  • 7.1 Introduction
  • 7.2 On-Premise
  • 7.3 Web-Based
  • 7.4 Cloud-Based

8 Global Genomics Market, By Technology

  • 8.1 Introduction
  • 8.2 Sequencing
    • 8.2.1 Next-Generation Sequencing (NGS)
    • 8.2.2 Sanger Sequencing
    • 8.2.3 Third-Generation Sequencing
  • 8.3 PCR
    • 8.3.1 qPCR
    • 8.3.2 dPCR
  • 8.4 Microarrays
  • 8.5 CRISPR
  • 8.6 Epigenomics

9 Global Genomics Market, By Application

  • 9.1 Introduction
  • 9.2 Diagnostics
    • 9.2.1 Cancer Diagnostics
    • 9.2.2 Rare Disease Diagnostics
    • 9.2.3 Infectious Disease Diagnostics
  • 9.3 Drug Discovery & Development
  • 9.4 Forensic Genomics
  • 9.5 Precision Medicine
  • 9.6 Agriculture & Animal Research
  • 9.7 Other Applications

10 Global Genomics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals & Clinics
  • 10.3 Diagnostic Laboratories
  • 10.4 Research & Academic Institutions
  • 10.5 Pharmaceutical & Biotechnology Companies
  • 10.6 Contract Research Organizations (CROs)

11 Global Genomics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Illumina
  • 13.2 Eurofins Scientific
  • 13.3 Thermo Fisher Scientific
  • 13.4 GenScript Biotech
  • 13.5 BGI Genomics
  • 13.6 Intellia Therapeutics
  • 13.7 Agilent Technologies
  • 13.8 CRISPR Therapeutics
  • 13.9 Roche
  • 13.10 Oxford Nanopore Technologies
  • 13.11 Bio-Rad Laboratories
  • 13.12 Pacific Biosciences
  • 13.13 QIAGEN
  • 13.14 10x Genomics
  • 13.15 Natera

List of Tables

  • Table 1 Global Genomics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Genomics Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Genomics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Genomics Market Outlook, By Sequencers & Amplifiers (2024-2032) ($MN)
  • Table 5 Global Genomics Market Outlook, By Sample Preparation Instruments (2024-2032) ($MN)
  • Table 6 Global Genomics Market Outlook, By DNA/RNA Analyzers (2024-2032) ($MN)
  • Table 7 Global Genomics Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 8 Global Genomics Market Outlook, By Reagents & Kits (2024-2032) ($MN)
  • Table 9 Global Genomics Market Outlook, By Panels & Chips (2024-2032) ($MN)
  • Table 10 Global Genomics Market Outlook, By Software & Services (2024-2032) ($MN)
  • Table 11 Global Genomics Market Outlook, By Bioinformatics Software (2024-2032) ($MN)
  • Table 12 Global Genomics Market Outlook, By Data Analysis Services (2024-2032) ($MN)
  • Table 13 Global Genomics Market Outlook, By Cloud-based Solutions (2024-2032) ($MN)
  • Table 14 Global Genomics Market Outlook, By Maintenance & Support Services (2024-2032) ($MN)
  • Table 15 Global Genomics Market Outlook, By Function (2024-2032) ($MN)
  • Table 16 Global Genomics Market Outlook, By Genome Sequencing (2024-2032) ($MN)
  • Table 17 Global Genomics Market Outlook, By Epigenomic Analysis (2024-2032) ($MN)
  • Table 18 Global Genomics Market Outlook, By Gene Expression Profiling (2024-2032) ($MN)
  • Table 19 Global Genomics Market Outlook, By Genotyping (2024-2032) ($MN)
  • Table 20 Global Genomics Market Outlook, By Delivery Model (2024-2032) ($MN)
  • Table 21 Global Genomics Market Outlook, By On-Premise (2024-2032) ($MN)
  • Table 22 Global Genomics Market Outlook, By Web-Based (2024-2032) ($MN)
  • Table 23 Global Genomics Market Outlook, By Cloud-Based (2024-2032) ($MN)
  • Table 24 Global Genomics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 25 Global Genomics Market Outlook, By Sequencing (2024-2032) ($MN)
  • Table 26 Global Genomics Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 27 Global Genomics Market Outlook, By Sanger Sequencing (2024-2032) ($MN)
  • Table 28 Global Genomics Market Outlook, By Third-Generation Sequencing (2024-2032) ($MN)
  • Table 29 Global Genomics Market Outlook, By PCR (2024-2032) ($MN)
  • Table 30 Global Genomics Market Outlook, By qPCR (2024-2032) ($MN)
  • Table 31 Global Genomics Market Outlook, By dPCR (2024-2032) ($MN)
  • Table 32 Global Genomics Market Outlook, By Microarrays (2024-2032) ($MN)
  • Table 33 Global Genomics Market Outlook, By CRISPR (2024-2032) ($MN)
  • Table 34 Global Genomics Market Outlook, By Epigenomics (2024-2032) ($MN)
  • Table 35 Global Genomics Market Outlook, By Application (2024-2032) ($MN)
  • Table 36 Global Genomics Market Outlook, By Diagnostics (2024-2032) ($MN)
  • Table 37 Global Genomics Market Outlook, By Cancer Diagnostics (2024-2032) ($MN)
  • Table 38 Global Genomics Market Outlook, By Rare Disease Diagnostics (2024-2032) ($MN)
  • Table 39 Global Genomics Market Outlook, By Infectious Disease Diagnostics (2024-2032) ($MN)
  • Table 40 Global Genomics Market Outlook, By Drug Discovery & Development (2024-2032) ($MN)
  • Table 41 Global Genomics Market Outlook, By Forensic Genomics (2024-2032) ($MN)
  • Table 42 Global Genomics Market Outlook, By Precision Medicine (2024-2032) ($MN)
  • Table 43 Global Genomics Market Outlook, By Agriculture & Animal Research (2024-2032) ($MN)
  • Table 44 Global Genomics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 45 Global Genomics Market Outlook, By End User (2024-2032) ($MN)
  • Table 46 Global Genomics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 47 Global Genomics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 48 Global Genomics Market Outlook, By Research & Academic Institutions (2024-2032) ($MN)
  • Table 49 Global Genomics Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 50 Global Genomics Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.